Fine-mapping naturally occurring NY-ESO-1 antibody epitopes in melanoma patients' sera using short overlapping peptides and full-length recombinant protein

Molecular Immunology

Volumn 54, Issue 3-4, 2013, Pages 465-471

  Komatsu, Nobukazu ^a,b   Jackson, Heather M ^a   Chan, Kok fei ^a   Oveissi, Sara ^a   Cebon, Jonathan ^a   Itoh, Kyogo ^b   Chen, Weisan ^a,c  

^a LUDWIG INSTITUTE FOR CANCER RESEARCH   (Australia)

^b KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c LA TROBE UNIVERSITY   (Australia)

Author keywords

Antibody epitope; Cancer vaccine; NY ESO 1; Overlapping peptide; Recombinant protein

Indexed keywords

EPITOPE; NY ESO 1 ANTIGEN; RECOMBINANT PROTEIN;

ABSORPTION; ADULT; AGED; AMINO TERMINAL SEQUENCE; ANTIBODY RESPONSE; ARTICLE; B LYMPHOCYTE; CARBOXY TERMINAL SEQUENCE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; EPITOPE MAPPING; FEMALE; HUMAN; HUMORAL IMMUNITY; MALE; MELANOMA; PRIORITY JOURNAL; SEROLOGY;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, NEOPLASM; ANTIGENS, NEOPLASM; CANCER VACCINES; EPITOPE MAPPING; EPITOPES; FEMALE; HUMANS; IMMUNITY, HUMORAL; MALE; MELANOMA; MEMBRANE PROTEINS; MIDDLE AGED; PEPTIDES; RECOMBINANT PROTEINS;

EID: 84874354003     PISSN: 01615890     EISSN: 18729142     Source Type: Journal    
DOI: 10.1016/j.molimm.2013.01.014     Document Type: Article

References (25)

1. Aoki M., Ueda S., Nishikawa H., Kitano S., Hirayama M., Ikeda H., Toyoda H., Tanaka K., Kanai M., Takabayashi A., Imai H., Shiraishi T., Sato E., Wada H., Nakayama E., Takei Y., Katayama N., Shiku H., Kageyama S. Antibody responses against NY-ESO-1 and HER2 antigens in patients vaccinated with combinations of cholesteryl pullulan (CHP)-NY-ESO-1 and CHP-HER2 with OK-432. Vaccine, Netherlands 2009, 6854-6861.
2. Chen Y.T., Scanlan M.J., Sahin U., Tureci O., Gure A.O., Tsang S., Williamson B., Stockert E., Pfreundschuh M., Old L.J. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proceedings of the National Academy of Sciences of the United States of America 1997, 94:1914-1918.
3. Chen Q., Jackson H., Parente P., Luke T., Rizkalla M., Tai T.Y., Zhu H.C., Mifsud N.A., Dimopoulos N., Masterman K.A., Hopkins W., Goldie H., Maraskovsky E., Green S., Miloradovic L., McCluskey J., Old L.J., Davis I.D., Cebon J., Chen W. Immunodominant CD4+ responses identified in a patient vaccinated with full-length NY-ESO-1 formulated with ISCOMATRIX adjuvant. Proceedings of the National Academy of Sciences of the United States of America 2004, 9363-9368.
4. Davis I.D., Chen W., Jackson H., Parente P., Shackleton M., Hopkins W., Chen Q., Dimopoulos N., Luke T., Murphy R., Scott A.M., Maraskovsky E., McArthur G., MacGregor D., Sturrock S., Tai T.Y., Green S., Cuthbertson A., Maher D., Miloradovic L., Mitchell S.V., Ritter G., Jungbluth A.A., Chen Y.T., Gnjatic S., Hoffman E.W., Old L.J., Cebon J.S. Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4+ and CD8+ T cell responses in humans. Proceedings of the National Academy of Sciences of the United States of America 2004, 101:10697-10702.
5. Fossa A., Berner A., Fossa S.D., Hernes E., Gaudernack G., Smeland E.B. NY-ESO-1 protein expression and humoral immune responses in prostate cancer. Prostate 2004, 59:440-447.
6. Gnjatic S., Atanackovic D., Jager E., Matsuo M., Selvakumar A., Altorki N.K., Maki R.G., Dupont B., Ritter G., Chen Y.T., Knuth A., Old L.J. Survey of naturally occurring CD4+ T cell responses against NY-ESO-1 in cancer patients: correlation with antibody responses. Proceedings of the National Academy of Sciences of the United States of America 2003, 8862-8867.
7. Hua R.H., Chen N.S., Qin C.F., Deng Y.Q., Ge J.Y., Wang X.J., Qiao Z.J., Chen W.Y., Wen Z.Y., Liu W.X., Hu S., Bu Z.G. Identification and characterization of a virus-specific continuous B-cell epitope on the PrM/M protein of Japanese encephalitis Virus: potential application in the detection of antibodies to distinguish Japanese encephalitis Virus infection from West Nile Virus and Dengue Virus infections. Virology Journal 2010, 7.
8. Hunder N.N., Wallen H., Cao J., Hendricks D.W., Reilly J.Z., Rodmyre R., Jungbluth A., Gnjatic S., Thompson J.A., Yee C. Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. New England Journal of Medicine 2008, 358:2698-2703.
9. Jager E., Nagata Y., Gnjatic S., Wada H., Stockert E., Karbach J., Dunbar P.R., Lee S.Y., Jungbluth A., Jager D., Arand M., Ritter G., Cerundolo V., Dupont B., Chen Y.T., Old L.J., Knuth A. Monitoring CD8T cell responses to NY-ESO-1: correlation of humoral and cellular immune responses. Proceedings of the National Academy of Sciences of the United States of America 2000, 97:4760-4765.
10. Jager E., Karbach J., Gnjatic S., Neumann A., Bender A., Valmori D., Ayyoub M., Ritter E., Ritter G., Jager D., Panicali D., Hoffman E., Pan L., Oettgen H., Old L.J., Knuth A. Recombinant vaccinia/fowlpox NY-ESO-1 vaccines induce both humoral and cellular NY-ESO-1-specific immune responses in cancer patients. Proceedings of the National Academy of Sciences of the United States of America 2006, 14453-14458.
11. Jäger E., Chen Y.T., Drijfhout J.W., Karbach J., Ringhoffer M., Jäger D., Arand M., Wada H., Noguchi Y., Stockert E., Old L.J., Knuth A. Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes. Journal of Experimental Medicine 1998, 187:265-270.
12. Kawabata R., Wada H., Isobe M., Saika T., Sato S., Uenaka A., Miyata H., Yasuda T., Doki Y., Noguchi Y., Kumon H., Tsuji K., Iwatsuki K., Shiku H., Ritter G., Murphy R., Hoffman E., Old L.J., Monden M., Nakayama E. Antibody response against NY-ESO-1 in CHP-NY-ESO-1 vaccinated patients. International Journal of Cancer 2007, 120:2178-2184.
13. Mashino K., Sadanaga N., Tanaka F., Yamaguchi H., Nagashima H., Inoue H., Sugimachi K., Mori M. Expression of multiple cancer-testis antigen genes in gastrointestinal and breast carcinomas. British Journal of Cancer 2001, 85(5):713-720.
14. Murphy R., Green S., Ritter G., Cohen L., Ryan D., Woods W., Rubira M., Cebon J., Davis I.D., Sjolander A., Kypridis A., Kalnins H., McNamara M., Moloney M.B., Ackland J., Cartwright G., Rood J., Dumsday G., Healey K., Maher D., Maraskovsky E., Chen Y.T., Hoffman E.W., Old L.J., Scott A.M. Recombinant NY-ESO-1 cancer antigen: production and purification under cGMP conditions. Preparative Biochemistry and Biotechnology 2005, 35:119-134.
15. Nicholaou T., Ebert L.M., Davis I.D., McArthur G.A., Jackson H., Dimopoulos N., Tan B., Maraskovsky E., Miloradovic L., Hopkins W., Pan L., Venhaus R., Hoffman E.W., Chen W., Cebon J., Regulatory T-cell-mediated attenuation of T-cell responses to the NY-ESO-1 ISCOMATRIX vaccine in patients with advanced malignant melanoma. Clinical Cancer Research 2009, 15:2166-2173.
16. Preuss K.D., Regitz E., Neumann F., Pfreundschuh M. B-cell epitopes from the cancer testis antigen NY-ESO-1. International Journal of Cancer 2006, 118:253.
17. Robbins P.F., Morgan R.A., Feldman S.A., Yang J.C., Sherry R.M., Dudley M.E., Wunderlich J.R., Nahvi A.V., Helman L.J., Mackall C.L., Kammula U.S., Hughes M.S., Restifo N.P., Raffeld M., Lee C.C., Levy C.L., Li Y.F., El-Gamil M., Schwarz S.L., Laurencot C., Rosenberg S.A. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. Journal of Clinical Oncology 2011, 29:917-924.
18. Scanlan M.J., Gure A.O., Jungbluth A.A., Old L.J., Chen Y.T. Cancer/testis antigens: an expanding family of targets for cancer immunotherapy. Immunological Reviews 2002, 188:22-32.
19. Schnurr M., Chen Q., Shin A., Chen W., Toy T., Jenderek C., Green S., Miloradovic L., Drane D., Davis I.D., Villadangos J., Shortman K., Maraskovsky E., Cebon J. Tumor antigen processing and presentation depend critically on dendritic cell type and the mode of antigen delivery. Blood 2005, 105:2465-2472.
20. Stavnezer J., Amemiya C.T. Evolution of isotype switching. Seminars in Immunology 2004, 16:257-275.
21. Stockert E., Jager E., Chen Y.T., Scanlan M.J., Gout I., Karbach J., Arand M., Knuth A., Old L.J. A survey of the humoral immune response of cancer patients to a panel of human tumor antigens. Journal of Experimental Medicine 1998, 187:1349-1354.
22. Svobodová S., Browning J., MacGregor D., Pollara G., Scolyer R.A., Murali R., Thompson J.F., Deb S., Azad A., Davis I.D., Cebon J.S. Cancer-testis antigen expression in primary cutaneous melanoma has independent prognostic value comparable to that of Breslow thickness, ulceration and mitotic rate. European Journal of Cancer 2011, 47:460-469.
23. Valmori D., Souleimanian N.E., Hesdorffer C.S., Ritter G., Old L.J., Ayyoub M. Identification of B cell epitopes recognized by antibodies specific for the tumor antigen NY-ESO-1 in cancer patients with spontaneous immune responses. Clinical Immunology 2005, 24-30.
24. Zarour H.M., Maillere B., Brusic V., Coval K., Williams E., Pouvelle-Moratille S., Castelli F., Land S., Bennouna J., Logan T., Kirkwood J.M. NY-ESO-1 119-143 is a promiscuous major histocompatibility complex class II T-helper epitope recognized by Th1- and Th2-type tumor-reactive CD4+ T cells. Cancer Research 2002, 62:213-218.
25. Zeng G., Aldridge M.E., Wang Y., Pantuck A.J., Wang A.Y., Liu Y.X., Han Y., Yuan Y.H., Robbins P.F., Dubinett S.M., deKernion J.B., Belldegrun A.S. Dominant B cell epitope from NY-ESO-1 recognized by sera from a wide spectrum of cancer patients: implications as a potential biomarker. International Journal of Cancer 2005, 114:268-273.